Curcumin exerts anti-tumor effects on diffuse large B cell lymphoma via regulating PPARγ expression

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Diffuse large B cell lymphoma (DLBCL) exhibits significant heterogeneity, leading to treatment resistance and relapse in many patients.
• Existing therapeutic regimens for DLBCL are insufficient, necessitating the exploration of novel treatment strategies.
• Curcumin, a compound with demonstrated anti-tumor properties in various cancers, presents a potential candidate for DLBCL therapy.

Purpose of the Study:

• To investigate the anti-proliferative and mechanistic effects of curcumin on human DLBCL cells in vitro and in vivo.
• To elucidate the molecular pathways targeted by curcumin in DLBCL, focusing on PPARγ and the Akt/mTOR pathway.
• To evaluate the therapeutic potential of curcumin as a novel treatment approach for DLBCL.

Main Methods:

• In vitro and in vivo studies using human DLBCL cell lines.
• Assessment of cell viability, apoptosis, and cell cycle progression following curcumin treatment.
• Pharmacological modulation of PPARγ activity using agonists (rosiglitazone) and antagonists (GW9662) to confirm pathway involvement.
• Analysis of PPARγ expression and Akt/mTOR pathway activation.

Main Results:

• Curcumin significantly inhibited DLBCL cell viability in a dose- and time-dependent manner.
• Curcumin treatment promoted cancer cell apoptosis and induced cell cycle arrest at the G2 phase.
• These effects were mediated by the upregulation of Peroxisome proliferator-activated receptor gamma (PPARγ) and the inactivation of the Akt/mTOR signaling pathway.
• PPARγ antagonism partially reversed curcumin's effects, while agonism enhanced them, confirming PPARγ's role.

Conclusions:

• Curcumin demonstrates significant anti-proliferative effects on DLBCL cells, primarily through the upregulation of PPARγ.
• The inactivation of the Akt/mTOR pathway is a key mechanism underlying curcumin's efficacy in DLBCL.
• Curcumin represents a promising therapeutic agent and a potential molecular target for novel DLBCL treatment strategies.